Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Pembrolizumab in Metastatic Urothelial Cancer
NCT02500121Phase 2Completed
- Start
- Nov 2015
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in urothelial carcinoma (UC). Started Nov 2015; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02500121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500121.